Live
- A Guide to Temperature and Humidity Standards in Data Center Server Rooms
- Gadwal collector briefs on details of voters
- Jupally Krishna Rao takes part in Alampur rallu
- Bharath Prasad files 3rd Nomination
- Baisakh Month: A Time of Auspicious Beginnings and Sacred Festivals
- Oust BJD govt for overall development, says Shah
- Unveiling the Hidden Gems: Surprising Health Benefits of Garlic Peels
- Overcoming Sleep Struggles: A Comprehensive Guide to a Restful Night
- RTC bus hit the auto
- MLA Kuchukula Rajesh Reddy participated in the Birappa festival
Ipca open offer for 26% stake in Krebs Bio opens on Nov 9
Drug maker Ipca Laboratories will begin an open offer to acquire 26 per cent additional stake in Hyderabad-based Krebs Biochemicals on November 9. It will end on November 24, Ipca Laboratories said in a filing.
New Delhi : Drug maker Ipca Laboratories will begin an open offer to acquire 26 per cent additional stake in Hyderabad-based Krebs Biochemicals on November 9. It will end on November 24, Ipca Laboratories said in a filing.
IPCA is making an open offer as per market regulator Sebi requirements to acquire 35,73,515 equity shares, amounting to 26 per cent stake, of Rs 10 each at a price of Rs 54 per share for a total consideration of Rs 19.29 crore, it added.
Mumbai-based Ipca had acquired 18,00,000 equity shares in Krebs Biochemicals & Industries in February this year and entered into an MoU with the promoters of the latter envisaging acquisition of joint control of the management.
It currently holds 31.38 per cent of the current paid up share capital of Krebs. The control will help Ipca consolidate its position. Krebs has expertise in chemical synthesis, fermentation and enzymatic technologies. Besides it also has two US Food and Drug Administration (USFDA) approved facilities in Visakhapatnam and Nellore districts.
